HAS Healthcare Expands: Acquires Cerbios-Pharma with 65 Equity Support

HAS Healthcare Advanced Synthesis SA, a prominent developer and producer of pharmaceutical active ingredients, plans to acquire Cerbios-Pharma SA, a globally recognized manufacturer of chemical and biological APIs. This acquisition is strategically supported by 65 Equity Partners, which will hold a 40% stake while the Braglia family remains the majority stakeholder. The merger promises to create a complementary CDMO leader by amalgamating their strengths in production, chemistry, biology, and their technological capabilities. This move is part of a wider initiative to enhance the delivery of innovative pharmaceutical solutions, driven by increasing demands for complex therapies across therapeutic areas. The acquisition remains subject to regulatory and fiscal approvals. The collaboration will bolster the reputation of the Swiss pharmaceutical industry, notably in the Tessin region, and aims to expand their global market leadership through strategic growth and innovation.